华润医药(03320)：天士力医药上半年归母净利约7.75亿元，同比增长16.97%

Core Viewpoint - China Resources Pharmaceutical (03320) reported Tianshili Pharmaceutical's performance for the first half of 2025, showing a slight decline in total revenue but an increase in net profit attributable to shareholders [1] Financial Performance - Total revenue for the first half of 2025 was approximately 4.288 billion yuan, representing a year-on-year decrease of 1.91% [1] - Net profit attributable to shareholders was about 775 million yuan, reflecting a year-on-year increase of 16.97% [1] - Basic earnings per share were reported at 0.52 yuan [1]